BFM
HBIO icon

Boothbay Fund Management’s Harvard Bioscience HBIO Stock Holding History

Boothbay Fund Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-115,140
Closed -$2.43M – 1554
2024
Q4 		$2.43M Sell
115,140
-18,442
-14% -$424K 0.06% 393
2024
Q3 		$3.59M Hold
133,582
– – 0.08% 336
2024
Q2 		$3.81M Sell
133,582
-849
-0.6% -$29.8K 0.09% 303
2024
Q1 		$5.7M Sell
134,431
-1,771
-1% -$79.6K 0.11% 188
2023
Q4 		$7.29M Buy
136,202
+8,750
+7% +$395K 0.19% 110
2023
Q3 		$5.48M Buy
127,452
+10,027
+9% +$463K 0.13% 191
2023
Q2 		$6.45M Sell
117,425
-6,085
-5% -$334K 0.14% 161
2023
Q1 		$5.19M Buy
123,510
+16,227
+15% +$481K 0.11% 244
2022
Q4 		$2.97M Buy
107,283
+68,012
+173% +$1.68M 0.07% 427
2022
Q3 		$1M Buy
39,271
+5,105
+15% +$169K 0.03% 864
2022
Q2 		$1.23M Buy
34,166
+28,166
+469% +$1.27M 0.03% 731
2022
Q1 		$373K Buy
+6,000
New +$355K 0.01% 1478

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's HBIO Position: Q1 2025 in Review

Boothbay Fund Management sold out of Harvard Bioscience (HBIO) in Q1 2025, closing a stake of 115,140 shares — an estimated $2.43M sold.

Boothbay Fund Management first reported a position in HBIO in Q1 2022 and held it in 12 quarters. The position peaked at $7.29M in Q4 2023. 91 funds tracked by Wall St. Rank hold HBIO as of Q1 2025.

  • Boothbay Fund Management reported no remaining Harvard Bioscience position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 115,140 Harvard Bioscience shares in Q1 2025, an estimated $2.43M.
  • Boothbay Fund Management first reported a position in Harvard Bioscience in Q1 2022 and held it in 12 quarters.
  • Boothbay Fund Management's Harvard Bioscience position peaked at $7.29M in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.